
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is expected to face some challenges, but overall has a strong track record and outlook due to their focus on cutting-edge technology and market expansion, as well as their commitment to ethical and responsible business practices. Their financials show positive trends, with a 2022 revenue growth rate of 9.1% and a gross profit margin of 72.6%. Their diverse product offerings and global presence also make them well-positioned for future growth.
Bears say
Boston Scientific is facing challenges in its Urology and CRM businesses and these challenges, along with increased R&D expenses, have caused a decrease in operating margin. Additionally, the company's guidance for 2026 has been lowered, with slower growth expected in important products such as FARAPULSE and WATCHMAN. These factors lead to a negative outlook for the stock's performance in the near future.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares